Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

NCT05602194 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT05602194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05602194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 24, 2023
Completion date
December 30, 2028
Enrollment
440 (estimated)
Sites
228

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia, b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, b acute lymphoblastic leukemia, bcr-abl1-like, lymphoblastic lymphoma, mixed phenotype acute leukemia, t acute lymphoblastic leukemia